May 2023/JCEM: This scientific statement expands the Society’s 2012 statement by focusing on endocrine disease disparities in the pediatric population and sexual and gender minority populations. Read the Statement.
June 2014/Endocrine Reviews: Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. Read the Statement.
April 2016/JCEM: Custom-compounded bioidentical hormone therapy (HT) has become widely used in current endocrine practice, which has led to unnecessary risks with treatment. Read the Statement.
September 2012/JCEM: Several themes emerged in the statement, including a need for basic science, population-based, translational and health services studies to explore underlying mechanisms contributing to endocrine health disparities. Read the Statement.